Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study
Research output: Contribution to journal › Journal article › Research › peer-review
Cardiovascular (CV) hospitalization is a predictor of CV mortality and has a negative impact on patients' quality of life. The primary endpoint of A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENTs with Atrial fibrillation/atrial flutter (ATHENA), a composite of first CV hospitalization or death from any cause, was significantly reduced by dronedarone. This post hoc analysis evaluated the secondary endpoint of CV hospitalization and the clinical benefit of dronedarone on the number and duration of CV hospitalizations in patients with atrial fibrillation (AF).
Original language | English |
---|---|
Journal | Europace |
Volume | 13 |
Issue number | 8 |
Pages (from-to) | 1118-26 |
Number of pages | 9 |
ISSN | 1099-5129 |
DOIs | |
Publication status | Published - 2011 |
ID: 40200136